There is plenty of evidence – and growing societal understanding worldwide – that cannabis alleviates the negative symptoms of serious health conditions.
To accelerate this effect, in tackling problems including chronic pain, mental health issues and nervous disorders, organism company, Ginkgo Bioworks and the Cronos Group, a vertically integrated cannabis company, have agreed a ‘landmark partnership to produce cultured cannabinoids’, the pair confirmed today. Ginko’s software for engineering biology, married with the ‘deep expertise in plant genetics’ Cronos, is a great match-up, and likely to lead to products that allow people to live better lives.
“We are thrilled to partner with Ginkgo; their biological engineering capabilities and disruptive technology platform are unrivaled. Together we can revolutionise the cannabis industry,” said Mike Gorenstein, CEO of Cronos Group.
Watch this space.